{
  "retracted": false,
  "timestamp": 1588291200000,
  "updates": [
    {
      "timestamp": 1591291327292,
      "identifier": {
        "doi": "10.1016/j.kint.2020.03.009"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.kint.2019.09.013"
  },
  "journal": "Kidney International",
  "publisher": "Elsevier BV",
  "title": "Corrigendum to “van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.” Kidney Int. 2020;97:202–212"
}
